Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Mapatumumab · HGS-1012

Monoclonal antibody · Agonist of TRAIL-R1 (tumor necrosis factor-related apoptosis-inducing ligand receptor 1) (TNFRSF10A) · developed by Human Genome Sciences Inc., a GSK Company

Phase 1/2 Most advanced trial (none active)
GSK Developer

What is Mapatumumab?

Mapatumumab is a fully human agonistic monoclonal antibody that binds and activates the TRAIL-R1 cell surface receptor, inducing apoptosis in malignant cells. It is studied in hepatocellular carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
HGS-1012
Drug type
Monoclonal antibody
Targets
TRAIL-R1 (tumor necrosis factor-related apoptosis-inducing ligand receptor 1) (TNFRSF10A)
Mechanism
Agonist of TRAIL-R1 (tumor necrosis factor-related apoptosis-inducing ligand receptor 1) (TNFRSF10A)
Pathways
apoptosis
Therapy area
Oncology
Developer
Human Genome Sciences Inc., a GSK Company (GSK)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
WZ1025JPGR

Conditions studied

Carcinoma, Hepatocellular

More from Human Genome Sciences Inc., a GSK Company

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the GSK page.

Follow GSK, the company behind Mapatumumab

See GSK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GSK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.